ASCO Lung Cancer Highlights, Part 3: Immunotherapy for Stage III NSCLC
http://cancerGRACE.org/...
Dr. David Gerber, University of Texas-Southwestern, reviews results of the START trial of tecemotide immunotherapy for stage III unresectable NSCLC.
GRACEcast 161 Lung
Author: cancergrace
Added: 08/14/2013
Source: Oncology Tube - Category: Cancer & Oncology Source Type: podcasts